Adverse Events Module

Adverse Events Module

For researchers submitting trial data to ClinicalTrials.gov, the Adverse Events module is one of four mandatory results sections. It requires reporting in three primary categories: All-Cause Mortality: A table tracking all deaths that occurred during the study, regardless of cause. Serious Adverse Events (SAEs): A tabular summary of events resulting in death, life-threatening conditions, hospitalization, or significant disability. Other Adverse Events: A table for non-serious events that exceed a specific frequency threshold, such as 5% within any study arm.

Adverse Events Module path is as follows:

Study -> Results Section -> Adverse Events Module -> Event Groups

Study -> Results Section -> Adverse Events Module -> Serious Events

Study -> Results Section -> Adverse Events Module -> Other Events

Adverse Events Module


Ignite Creation Date: 2025-12-24 @ 12:08 PM
Ignite Modification Date: 2025-12-25 @ 11:59 AM
NCT ID: NCT05931861
Description: None
Frequency Threshold: 5
Time Frame: Adverse events were collected from informed consent signature (Day 1) to Final visit (Day 36).
Study: NCT05931861
Study Brief: Performance and Safety Assessment of T2769 in Contact Lens Wearers With Dry Eye Symptoms.
Event Groups(If Any):

Event Groups

Title Description Deaths # Affected Deaths # At Risk Serious # Affected Serious # At Risk Other # Affected Other # At Risk View
T2769 One drop in each eye, from 3 to 6 times daily, at any time but only when patients are wearing their contact lenses. T2769: T2769: sodium hyaluronate 0.15%, Trehalose 3%, Naaga 2.45% in a 12.5 mL ABAKĀ® multi-dose bottle. 0 None 0 34 0 34 View
Serious Events(If Any):
Other Events(If Any):